Detalhe da pesquisa
1.
Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer: final 10-year analysis of the open-label, single-arm, phase 2 APT trial.
Lancet Oncol
; 24(3): 273-285, 2023 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36858723
2.
The epichaperome is an integrated chaperome network that facilitates tumour survival.
Nature
; 538(7625): 397-401, 2016 Oct 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-27706135
3.
Bridging the Gap Among Clinical Practice Guidelines for Pain Management in Cancer and Sickle Cell Disease.
J Natl Compr Canc Netw
; 18(4): 392-399, 2020 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-32259777
4.
Phase II Study of Weekly Paclitaxel with Trastuzumab and Pertuzumab in Patients with Human Epidermal Growth Receptor 2 Overexpressing Metastatic Breast Cancer: 5-Year Follow-up.
Oncologist
; 24(8): e646-e652, 2019 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-30602614
5.
Extending Aromatase-Inhibitor Adjuvant Therapy to 10 Years.
N Engl J Med
; 375(3): 209-19, 2016 Jul 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-27264120
6.
Local-regional recurrence in women with small node-negative, HER2-positive breast cancer: results from a prospective multi-institutional study (the APT trial).
Breast Cancer Res Treat
; 176(2): 303-310, 2019 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-31004299
7.
Copper-64 trastuzumab PET imaging: a reproducibility study.
Q J Nucl Med Mol Imaging
; 63(2): 191-198, 2019 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-27171605
8.
MicroRNA-335 inhibits tumor reinitiation and is silenced through genetic and epigenetic mechanisms in human breast cancer.
Genes Dev
; 25(3): 226-31, 2011 Feb 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-21289068
9.
Correlative imaging reveals physiochemical heterogeneity of microcalcifications in human breast carcinomas.
J Struct Biol
; 202(1): 25-34, 2018 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-29221896
10.
Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer.
N Engl J Med
; 372(2): 134-41, 2015 Jan 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-25564897
11.
Monosomy 17 in potentially curable HER2-amplified breast cancer: prognostic and predictive impact.
Breast Cancer Res Treat
; 167(2): 547-554, 2018 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-28986743
12.
Identification of risk factors for toxicity in patients with hormone receptor-positive advanced breast cancer treated with bevacizumab plus letrozole: a CALGB 40503 (alliance) correlative study.
Breast Cancer Res Treat
; 171(2): 325-334, 2018 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-29789969
13.
Breast carcinoma with 21-gene recurrence score lower than 18: rate of locoregional recurrence in a large series with clinical follow-up.
BMC Cancer
; 18(1): 42, 2018 01 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-29304773
14.
The Impact of Obesity on Breast Cancer.
Curr Oncol Rep
; 20(6): 47, 2018 04 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-29644507
15.
A phase I trial of ganetespib in combination with paclitaxel and trastuzumab in patients with human epidermal growth factor receptor-2 (HER2)-positive metastatic breast cancer.
Breast Cancer Res
; 19(1): 89, 2017 Aug 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-28764748
16.
Breast carcinoma with an Oncotype Dx recurrence score <18: Rate of distant metastases in a large series with clinical follow-up.
Cancer
; 123(1): 131-137, 2017 Jan 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-27526056
17.
Obesity and cancer: local and systemic mechanisms.
Annu Rev Med
; 66: 297-309, 2015.
Artigo
em Inglês
| MEDLINE | ID: mdl-25587653
18.
Cardiac Safety of Dual Anti-HER2 Therapy in the Neoadjuvant Setting for Treatment of HER2-Positive Breast Cancer.
Oncologist
; 22(6): 642-647, 2017 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-28341761
19.
Pathologic Complete Response with Neoadjuvant Doxorubicin and Cyclophosphamide Followed by Paclitaxel with Trastuzumab and Pertuzumab in Patients with HER2-Positive Early Stage Breast Cancer: A Single Center Experience.
Oncologist
; 22(2): 139-143, 2017 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-28167568
20.
The 21-gene recurrence score in special histologic subtypes of breast cancer with favorable prognosis.
Breast Cancer Res Treat
; 165(1): 65-76, 2017 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-28577081